# GLOW peptide: the GHK-Cu, BPC-157 and TB-500 research blend, set down as study plates

> GLOW peptide is a three-part research blend of GHK-Cu, BPC-157 and TB-500. An illustrated digest of what the constituent literature shows and the open questions, every quantitative claim cited.

Three peptides, three literatures, one reading-room. We set the constituents down as study plates, annotate the combination thesis, and keep the regulatory record in the margin — with every quantitative claim cited.

## What GLOW peptide is

GLOW peptide is a three-part research blend of GHK-Cu, BPC-157 and TB-500 — not a single molecule, and not an approved drug. It is a co-formulated combination of three distinct research peptides, drawn together because their published mechanisms point at the same target: tissue repair and skin renewal.

The three constituents do different work. GHK-Cu — the copper(II) chelate of the tripeptide glycyl-L-histidyl-L-lysine, INCI name Copper Tripeptide-1 — is a matrix-remodeling, collagen-stimulating copper peptide and the skin lead of the blend. BPC-157 is a synthetic stable pentadecapeptide (sequence GEPPPGKPADDAGLV) derived from a gastric body-protection protein; in research it is cytoprotective and pro-angiogenic. TB-500 is an acetylated heptapeptide (Ac-LKKTETQ) corresponding to the actin-binding region of thymosin beta-4, studied for cell migration and reduced scarring.

There are no controlled clinical trials of the **glow blend** itself. The evidence base is the literature on each constituent peptide, plus the mechanistic rationale for combining them [1][3][5]. That distinction runs through every page here: what the published studies establish at the constituent level, and what is asserted about the trio without having been tested as a trio.

Exact ratios are formulation-specific and not standardized; a commonly cited research-label convention is 10 mg BPC-157 / 10 mg TB-500 / 50 mg GHK-Cu per vial, which is a supplier labeling convention rather than a clinically validated dose [9]. The related KLOW blend adds KPV; the Wolverine blend is BPC-157 + TB-500 only.

## GLOW peptides: the three constituents

The **glow peptides** resolve to three named molecules, each with its own role in the combination thesis and its own machine identifiers on the record.

GHK-Cu (Copper Tripeptide-1, CAS 89030-95-5, MW ~402.9 Da) carries the matrix-and-collagen leg. The free GHK sequence occurs within human type I collagen and circulates in plasma, declining with age; as the copper complex it stimulates dermal fibroblast synthesis of collagen, elastin and glycosaminoglycans [1][2]. BPC-157 (MW ~1419 Da) carries the cytoprotective and pro-angiogenic leg, up-regulating VEGFR2 and accelerating connective-tissue healing in animal models [3][4]. TB-500 (MW ~889 Da, parent: thymosin beta-4, gene TMSB4X) carries the cell-migration and anti-scarring leg, sequestering G-actin to drive cell movement [5][6].

The identifiers matter because the same names get used loosely online. "TB-500" in commerce is the Ac-LKKTETQ heptapeptide, but most of the efficacy data uses full-length thymosin beta-4 — it is not established that the fragment reproduces the parent protein's effects [6]. See [GHK-Cu, BPC-157 and TB-500 constituents](/) below in the comparison register, and [the research on the GLOW blend](/research) for the mechanism in depth.

## GLOW as a peptide stack vs the KLOW and Wolverine blends

As a **glow peptide stack**, GLOW sits in a small family of clinic- and supplier-formulated combinations that share the BPC-157 + TB-500 repair pairing and differ at the edges. GLOW is GHK-Cu + BPC-157 + TB-500 — the addition of the copper tripeptide is what tilts it toward skin and aesthetics. The KLOW blend adds KPV, an anti-inflammatory tripeptide, to the GLOW trio. The Wolverine blend strips back to BPC-157 + TB-500 only, the pure tissue-repair pairing without the skin lead.

None of these blends has been tested as a unit in a controlled human trial; the family is best understood as a set of mechanistic recipes rather than validated products. The combination rationale for GLOW specifically is complementary coverage — a matrix-building signal, a vascular signal and a cell-mobility signal — which is a thesis about mechanism, not a demonstration of synergy [1][3][5].

## What the constituent literature shows

The strongest individual findings sit at the constituent level and are worth surfacing plainly. In a rat full-thickness wound model, thymosin beta-4 — the parent of TB-500 — increased re-epithelialization by 42% over saline controls at day 4 and 61% at day 7, and as little as 10 pg stimulated cell migration two- to three-fold [5]. BPC-157 accelerated healing of a fully transected rat Achilles tendon across biomechanical, functional and microscopic measures, and stimulated tendocyte outgrowth in vitro [3]. A canonical skin-regeneration review establishes GHK-Cu's matrix-synthesis profile — collagen, dermatan sulfate, chondroitin sulfate and decorin — and its cosmetic improvements in skin elasticity, density and firmness [1].

Those are real results, and they are also constituent-level and largely preclinical. A 2026 Sports Medicine review that names BPC-157, TB-500 and GHK-Cu together concluded that many unapproved peptides show favorable tissue-repair outcomes in animal models but that rigorous human safety data are scarce and the potential for harm is real [10]. That is the honest frame for the whole blend: promising parts, an untested whole.

Dig deeper in [the research on the GLOW blend](/research), see the skin and aesthetics record on [GLOW peptide for skin research](/skin-research), or read [the frequently asked questions about GLOW](/faq).

## What is GLOW peptide?

GLOW peptide is a non-standardized multi-peptide research blend, most commonly GHK-Cu + BPC-157 + TB-500, formulated by clinics and suppliers rather than a single approved drug. The name resolves consistently to that trio across consumer and clinic sources, but ratios and purity vary by source and the blend has never been a single regulated product [9].

## What does the GLOW peptide do?

Its three constituents are studied for complementary tissue-repair and skin-renewal mechanisms: matrix remodeling and collagen synthesis (GHK-Cu), angiogenesis and cytoprotection (BPC-157), and cell migration with reduced scarring (TB-500). These are constituent-level research roles drawn from the published literature, not a demonstrated effect of the blend itself [1][3][5].

## What does GLOW peptide have in it?

Most commonly GHK-Cu (a collagen-stimulating copper peptide), BPC-157 (a body-protection pentadecapeptide) and TB-500 (a thymosin beta-4 fragment). Exact ratios are formulation-specific and not standardized; a commonly cited research-label convention is 10 mg BPC-157 / 10 mg TB-500 / 50 mg GHK-Cu per vial, a supplier labeling convention rather than a validated dose [9].

## What peptides are in the GLOW blend?

GHK-Cu, BPC-157 and TB-500. The related KLOW blend adds KPV, a fourth tripeptide; the Wolverine blend is BPC-157 + TB-500 only, without the GHK-Cu skin lead. GLOW is the three-peptide configuration whose copper tripeptide gives it its skin-and-aesthetics emphasis [9].

---

An illustrated night-lithograph of the GLOW peptide literature — GHK-Cu, BPC-157 and TB-500 set down as engraved study plates and weighed against their sources, with no clinic behind the gaslight and nothing here to dispense.